Merit Medical Systems (MMSI) Earnings Date & Reports

Key Takeaways

• Merit Medical Systems (MMSI) reported third-quarter 2026 revenue of $416.2 million, up 8.4% year over year, with organic constant currency growth of 9%.
• Non-GAAP earnings per share (EPS) came in at $1.12, ahead of the roughly $1.04 per share consensus estimate, while GAAP EPS was $0.70.
• Non-GAAP operating margin expanded to 21.3% from 19.7% in the prior-year quarter, while GAAP operating margin rose to 14.1% from 11.1%.
• Management raised full-year 2026 guidance, now projecting revenue of $1.635–$1.642 billion and non-GAAP EPS of $4.33–$4.37.
• The company also disclosed the acquisition of Solo Pace, Inc. for approximately $45 million, completed on October 13, 2026.
• For more context on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
• Investors can also explore Trending AI Robots to discover automated trading strategies across the market.

Earnings Context and Why It Matters

Merit Medical Systems is a global manufacturer of healthcare technology and disposable medical devices used across cardiology, radiology, oncology, and endoscopy. Its third-quarter report matters because it tests whether the company can sustain the momentum built in the first half of 2026, when stronger-than-expected results prompted management to raise its full-year outlook. Investors are also watching how Merit balances organic growth with a string of recent acquisitions and the divestiture of its DualCap product line, while managing tariff-related cost pressure. A 9% organic constant currency growth rate signals durable underlying demand, and the raised guidance suggests confidence in the balance of the year.

Reported Results

Merit Medical reported third-quarter 2026 revenue of $416.2 million, an increase of 8.4% on a reported basis. Constant currency revenue rose 8%, while constant currency organic revenue rose 9%. Non-GAAP net income was $67.4 million, or $1.12 per share, compared with $54.9 million, or $0.92 per share, in the prior-year period. GAAP net income was $42.3 million, or $0.70 per share, up from $27.8 million, or $0.46 per share, a year earlier.

Profitability improved across both measures. Non-GAAP operating margin reached 21.3%, up from 19.7% in the third quarter of 2025, while GAAP operating margin climbed to 14.1% from 11.1%. The company ended the quarter with cash and cash equivalents of $503.6 million and total debt obligations of $747.5 million, with roughly $697 million in available borrowing capacity.

Management also updated its full-year 2026 guidance, now expecting revenue of $1.635–$1.642 billion and non-GAAP EPS of $4.33–$4.37, an increase from the prior guidance of $1.631–$1.643 billion in revenue and $4.25–$4.35 in non-GAAP EPS.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. By surfacing trade ideas, trending stocks, and breakout candidates, the screener helps investors identify opportunities more efficiently than manual screening. For those monitoring names like Merit Medical Systems (MMSI) or seeking new setups, the AI Screener offers a streamlined way to narrow the market and focus on actionable candidates.

Market Reaction and Investor Sentiment

Heading into the report, shares of Merit Medical had been trading near record levels, reflecting elevated expectations after two consecutive quarters of beats. Analysts had projected roughly $1.04 per share in earnings on about $410 million in revenue, and the company's reported non-GAAP EPS of $1.12 and revenue of $416.2 million came in above those marks. The combination of accelerated organic growth, expanded operating margins, and a raised full-year outlook provided a positive signal to investors, though tariff uncertainty and the integration of recent acquisitions remain key watchpoints that could influence sentiment going forward.

Forward Outlook and Key Factors to Monitor

Merit Medical enters the final stretch of 2026 with raised full-year targets and several catalysts worth watching. The updated guidance calls for full-year revenue growth of about 8% and non-GAAP EPS growth of 13% to 14%, implying management expects momentum to continue into the fourth quarter.

One area to monitor is margin durability. The company's profitability improvement has been supported by pricing, product mix, and manufacturing efficiencies, but these gains must be weighed against ongoing tariff exposure and any input-cost volatility. Investors will also want to track how newly acquired businesses, including Solo Pace and earlier additions such as View Point Medical, contribute to organic and inorganic growth without diluting near-term profitability.

Balance sheet strength provides flexibility for further strategic activity, given cash of more than $500 million and available borrowing capacity of about $697 million. At the same time, integration execution across multiple recent acquisitions will be a key test of management's ability to sustain both growth and margins. As Merit builds toward its long-term strategic plan, the focus remains on whether it can convert strong top-line performance into consistent profitability and cash flow.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations